Home »


Prof. İhsan Gürsel




Bilkent University, Science Faculty,
Department of Molecular Biology and Genetics,
THORLAB-Therapeutic Oligonucleotide Research Laboratory.
Bilkent, 06800, Ankara, Turkey
+90-312-290 2408 (Work)
+90-312-266 5106 (Home)
+90-538-648-2010 (Mobile)
+90-312-266 5097(Fax)
20/Oct/1964, Lefke/Cyprus
Married, one son


Professor Immunology Higher Education Council, Turkey, 2014
Assoc Prof Cell Biology/Immunology Higher Education Council, Turkey, 1998
Ph.D. Biology Middle East Technical University, Turkey, 1995
M.Sc. Biology Middle East Technical University, Turkey, 1989
B.Sc. Biology Middle East Technical University, Turkey, 1987


2014- Professor, Bilkent University, Ankara, Turkey
2007-2014 Associate Professor, Bilkent University, Ankara, Turkey
2005-2007 Assistant Professor, Bilkent University, Ankara, Turkey
2001-2005 Senior Staff Scientist/Regulatory Personnel, US-FDA, Maryland, USA
1998-2001 Visiting Research Fellow (ORISE Fellow), US-FDA, Maryland, USA
1997-1998 Assistant Professor, Middle East Technical University, Ankara, Turkey
1996-1997 Lecturer, Middle East Technical University, Ankara, Turkey
1993-1994 Research Scientist, University of London, London, UK
1987-1995 Research Assistant, Middle East Technical University, Ankara, Turkey


Elected as a Full member of Science Academy of Turkey, 2013
Executive Committee member of the Turkish Society of Immunology, 2013-2016
Comptroller of Biomaterials and Tissue Engineering Society, 2010-2015
Management Committee Member of European Network on “Microvesicles and Exosomes in Health and Disease (ME-HAD)” European Cooperation in Science and Technology (COST ACTION- BM1202)
Management Committee Member of European Network on ” Action to Focus and Accelerate Cell-based Tolerance-inducing Therapies (FACTT)” European Cooperation in Science and Technology (COST ACTION- BM1305)
Executive Committee member of REGPOT: Strengthening of Materials Science and Nanotechnology Institute of Turkey as a National Centre of Excellence through European Integration (FP7 Regpot project 1 Feb 2008-1 Feb 2011).
Elected as an international expert panel member of the National Institute of Health (Pyrogenicity Testing Working Group, 2006-2007, NIH, USA).
Panel review member of several TUBITAK and FullBright grant applications.
External Reviewer of Scientific Research Grant Evaluation applications from Universities.


Frontiers in Immunology
Turkish Journal of Immunology

GRANTS (2005-present)

Investigation of Effects of Allergen Specific Immunotherapy on Cytokine Profile, Exosomes and T Lymphocytes,TUBITAK, SBAG-113S978, Start Date: July 2014 (Duration:30 months)
Budget: 383000 TL (171.000 $)

Improvement of FMDV vaccine potency in Cattle, Ministry of Industry and Trade (SANTEZ Grant) Start Date: July 2014 (Duration: 24 months)
Budget: 789.000 TL ($ 395.500)

TLR Ligand and Antigen Loaded Nanoliposomes as Cancer Vaccines, TÜBİTAK, SBAG-113S207, Start Date: October-2013 (Duration: 24 months)
Budget: 298.000 TL ($ 149.000)

Development of oligonucleotide based immune adjuvants for FMD vaccine, Ministry of Industry and Trade (SANTEZ Grant), Start Date: Jan. 2013 (Duration: 24 months),
Budget: 411.000 TL ($ 228.000)

DNA loaded exosomes and their use in vaccination and anti-cancer therapy, TUBITAK, SBAG-111S216, Start Date: November 2011 (Duration: 24 months),
Budget : 288,450 TL ($ 160.000)

Improving broiler chicken immune resistance by providing protection and reducing losses from stress and bacterial diseases with CpG DNA, Ministry of Industry and Trade (SANTEZ Grant), Start Date: Nov. 2009 (Duration: 24 months),
Budget: 1.068.000 TL ($ 590.000)

Biomedical Applications of DNA Nanoparticles, TUBITAK, SBAG-108S316, Start Date: March 2009 (Duration: 30 months)
Budget : 314,900 TL ($ 170.000)

Development of CpG ODN containing liposomal vaccines against pathogens, TUBITAK, SBAG-106S102, Start Date: August 2006 (Duration: 36 months),
Budget : 411.500 TL ($ 228.000 )

Biotherapeutic ODN: Use of CpG oligodeoxynucleotides to improve the immunogenicity of vaccines, FP6-Marie Curie International Reintegration Grant (MC-IRG-IG), Start Date: April 2006 (Duration: 24 months),
Budget : 80,000 Euro ($ 120.000)


  1. DM. Klinman, M. Gursel and I. Gursel, Methods of altering an immune response mediated by multimeric CpG oligodeoxynucleotides, (Patent pending, provisional publication date: 02-04-2011)
  2. DM. Klinman, M. Gursel and I. Gursel, Methods of altering an immune response induced by CpG oligodeoxynucleotides, (PCT Patent, publication number: WO/2007/027718, publication date: 08-03-2007)
  3. D. Verthelyi, I. Gursel, M. Gursel, R. Zeuner, and D.M. Klinman, Method of treating inflammatory arthropathies with suppressors of CpG oligodeoxynucleotides (PCT patent, publication number: WO/2004/012669, publication date: 02-23-2004).
  4. D.M. Klinman, M. Gursel, I. Gursel, R. Zeuner, and D. Verthelyi, Suppressors of CpG oligonucleotides and methods of use (PCT patent publication number: WO03027313, publication date 04-07-2003)
  5. D.M. Klinman, I. Gursel, KJ. Ishii, K. Kawakami, B.H. Joshi, and R.K. Puri., Use of sterically stabilized cationic liposomes to efficiently deliver CpG oligodeoxynucleotides in vivo (PCT patent, publication number: WO03040308, publication date: 05-15-2003).
  6. G. Gregoriadis, S.G. Antimisiaris, and I. Gursel, Liposomes containing particulate materials, (PCT Application: GB/94-02191, PCT Publication Number: WO 95/09610 (licensed in 7 different countries).
  7. D.M. Klinman and I. Gursel, KJ. Ishii,CpG Oligodeoxynucleotides encapsulated in sterically stabilized cationic liposomes as immunotherapeutic agents (USPTO# 7,666,674, 23/Feb/2010)
  8. D.M. Klinman, I. Gursel, and M. Gursel, Identification of DNA sequence motifs that suppress the immune response to CpG DNA, (US. Patent Pending, 2001, (DHHS Reference No. E-218-01/0).



Ph.D. Thesis: Use of microbial polyhydroxyalkanoates in the construction of biomedical drug release systems, February 1995, Supervisor: V. Hasirci (Middle East Technical University, Ankara, Turkey) and Co-supervisor: G. Gregoriadis (university of London, The School of Pharmacy, London, UK),

M.Sc. Thesis: Matrix entrapment of glucose oxidase by gamma-irradiation, September 1989, Supervisor: V. Hasirci, Middle East Technical University, Ankara, Turkey


Citations Received :
1. 2403, h – Factor : 26 (ISI Web of Knowledge, as of 23rd Nov 2014),
2. 2472, h – Factor : 26 (SCOPUS, as of 23rd Nov 2014)
3. 3359, h-factor: 29
(Google Scholar, http://scholar.google.com/citations?user=UPHRhNQAAAAJ&hl=en)


  1. S. Yildiz, E A lpdundar, B. Gungor, T. Kahraman, B. Bayyurt, I. Gursel, M. Gursel, Enhancement of Immunostimulatory Activity of Cyclic Dinucleotides through Complexation with a Cell Penetrating Peptide or Combined Use with CpG ODN, Eur. J. Immunol. (Waiting Editor`s Decision), (IF: 5.103)
  2. M. M. Aydin, T. Kahraman, F.C. Yagci, E. Akhan, K.C. Akcali, I. Gursel, Regression of the Liver Fibrosis by Suppressive Oligonucleotide, Biomaterials, (Waiting Editor`s Decision) (IF: 8.312)
  3. T. Kahraman, G. Gucluler, I. Gursel, Exosomes: Natural Nanovesicle Candidates Used in the Diagnosis and Treatment. Turk J. Immunol,2(2): 34-40 2014
  4. B. Bayyurt, I. Gursel, Inflammasome Induction and Immunostimulatory Effects of CpG-ODN Loaded Liposomes Containing DC-Cholesterol. Turk J. Immunol, 2(2):21-28, 2014
  5. G. Tincer, B. Bayyurt, Y.M. Arıca, I. Gursel, Chitosan polysaccharide suppress TLR dependent immune response”. Turk. J. Immunol. (under review)
  6. B. Gungor, FC Yagci, I. Gursel, M Gursel, Forging a Potent Vaccine Adjuvant: CpG ODN/Cationic Peptide Nanorings, OncoImmunology, e950166, 2014 (IF:6.298)
  7. B. Gungor, FC Yagci, G Tincer, B Bayyurt, E Alpdundar, S Yildiz, M Ozcan, I. Gursel, M. Gürsel CpG ODN Nanorings Induce IFNα from Plasmacytoid Dendritic Cells and Demonstrate Potent Vaccine Adjuvant Activity, Science Translational Medicine 6 (235), 235ra61, 2014 (IF:14.414) * Cover Story
  8. M Gursel, DM Klinman, I. Gursel, Plasmacytoid Dendritic Cell Response to CpG ODN Correlates with CXCL16 Expression and is Inhibited by ox-LDL, Mediators of Inflammation, 2013:312590, 2013 (IF:3.988)
  9. C. Sackesen, M. Akdis, O. Soyer, J. Zumkehr, B. Ruckert, O. KalaycI, S. S. Alkan, I. Gursel, C. A. Akdis, Suppression of B cell activation and IgE, IgA, IgG1 and IgG4 production by mammalian telomeric oligonucleotides , Allergy 68(5):593-603, 2013 (IF:6.271)
  10. O. Osmanagaoglu, F. Kiran, F.C. Yagci, I. Gursel, Immunomodulatory function and in vivo properties of Pediococcus pentosaceus OZF, apromising probiotic strain, 2012 Annals of Microbiology , pp. 1-8 (IF:0.689)
  11. S. Okay , E. Ozcengiz I. Gursel, G. Ozcengiz, Immunogenicity and protective efficacy of the recombinant Pasteurella lipoprotein E and outer membrane protein H from Pasteurella multocida A:3 in mice. Res Vet Sci., 93(3): 1261-1265, 2012, (IF:1.649)
  12. G. Bayramoglu, I. Gursel , M. Yilmaz, M.Y. Arica, Immobilization of laccase on itaconic acid grafted and Cu(II) ion chelated chitosan membrane for bioremediation of hazardous materials, J.Chem.Technol. Biotechnol., 8(4):530–539, 2012, (IF: 2.168)
  13. E. Birben, C. Saçkesen, S. Kazanı, G. Tinçer, C. Karaaslan, B. Durgunsu, I. Gursel, M. E. Wechsler, E. Israel, O. Kalaycı. The effects of an insertion in the 5′UTR of the AMCase on gene expression and pulmonary functions, Respir Med. 105(8):1160-69, 2011, (IF:2.475)
  14. G. Tincer, S. Yerlikaya, F.C. Yagci, T. Kahraman, O.M. Atanur, O. Erbatur, I. Gursel., Immunostimulatory activity of polysaccharide-poly(I:C) nanoparticles. Biomaterials. 32(18): 4275-82, 2011, (IF:8.415)
  15. E. Erikçi, M. Gursel, I. Gursel.,Differential immune activation following encapsulation of immunostimulatory CpG oligodeoxynucleotide in nanoliposomes. Biomaterials. Feb;32(6):1715-23. 2011 (IF:8.415)
  16. F.C. Yagci, O. Aslan, M. Gursel, G. Tincer, Y. Ozdamar, K. Karatepe, K.C. Akcali, I.Gursel, Mammalian telomeric DNA suppresses endotoxin induced uveitis. J Biol Chem. 2010 Jul 14. [Epub ahead of print] 285(37):28806-28811, 2010, (IF:5.330)
  17. G. Bayramoglu, I. Gursel, Y. Tunali, M. Y. Arica, Biosorption of phenol and 2-chlorophenol by Funalia trogii pellets, Biores.Technol. 100(10):2685-2691, 2009, (IF:4.980)
  18. MK. Abak, O. Aktas, R. Mammadov, I. Gursel, A. Dana, Parametrically coupled multiharmonic force imaging, Appl.Phys.Letts, 92(22): Article Number: 223113, 2008, (IF:3.840)
  19. S. Klaschik, I. Gursel, D.M. Klinman, CpG-mediated changes in gene expression identified by microarray analysis, Mol. Immunol., 44(6):1095-1104, 2007, (IF:3.200)
  20. M. Gürsel *, I. Gursel*, H.S. Mostowski, D.M. Klinman, CXCL16 influences the nature and specificity of CpG-induced immune activation, J. Immunol., 177(3):1575-1580, 2006 * equal contribution, (IF:5.788)
  21. D.M. Klinman, I. Gursel, S. Klaschik, L. Dong, D. Currie, H. Shirota, Therapeutic potential of oligonucleotides expressing immunosuppressive TTAGGG motifs, Ann. N.Y. Acad. Sci. 1058, 87-95, 2005, (IF:3.155)
  22. H. Shirota, I. Gursel, M. Gursel, D. M. Klinman, Suppressive oligodeoxynucleotides protect mice from lethal endotoxic shock, J. Immunol. 174(8):4579-4583, 2005, (IF:5.788)
  23. H. Xie, I. Gursel, B. Ivins, D.O`Hagan, J. Ulmer, D.M. Klinman, CpG oligodeoxynucleotides adsorbed onto PLG microparticles improve the immunogenicity and efficacy of anthrax vaccine, Infect. Immun. 73(2):828-833, 2005, (IF:4.165)
  24. D.M. Klinman, D. Currie, I. Gursel, D. Verthelyi, Use of CpG oligodeoxynucleotides as immune adjuvants, Immunol. Rev. 199:201-216, 2004, (IF:11.148)
  25. K.J. Ishii, I. Gursel, M. Gursel, D. M. Klinman, Immunotherapeutic utility of stimulatory and suppressive oligodeoxynucleotides, Curr. Op. Mol. Ther. 6(2):166-174, 2004, (IF:3.680)
  26. F. Takeshita, I. Gursel, K.J. Ishii, K. Suzuki, M. Gursel, D. M. Klinman, Signal transduction pathways mediated by the interaction of CpG DNA with toll-like receptor 9, Semin. Immunol. 16, 17-22, 2004, (IF:6.393)
  27. K.J. Ishii, K. Kawakami, I. Gursel, B.H. Joshi, D.M. Klinman, R.K. Puri. Anti-tumor therapy with bacterial DNA and toxin: complete regression of established tumor induced by liposomal CpG ODN plus IL-13 cytotoxin, Clin. Cancer Res. 9(17), 6516-6522, 2003, (IF:7.742)
  28. D. M. Klinman, R.A. Zeuner, H. Yamada, M. Gursel, D. Currie, I. Gursel, Regulation of CpG-induced immune activation by suppressive oligodeoxynucleotides, Ann. N.Y. Acad. Sci. 1002, 112-123, 2003, (IF:3.155)
  29. I. Gursel, M. Gursel, H. Yamada, F. Takeshita, K. J. Ishii, D. M. Klinman, Repetitive elements present in mammalian telomeres suppress CpG DNA induced immune activation, J. Immunol. 171:1393-1400, 2003 (this study was picked as the cover story: http://www.jimmunol.org/content/vol171/issue3/cover.shtml). (IF:5.788)
  30. A. Yagmurlu, M. Barlas, I. Gursel. I.H. Gokcora, Reduction of injury induced peritoneal adhesions by continuous release of streptokinase from a drug delivery system, Eur.Surg.Res. 35(1):46-49, 2003, (IF:0.932)
  31. H. Yamada, I. Gursel, F. Takeshita, J. Conover, K. J. Ishii, M. Gursel, S. Takeshita, and D. M. Klinman, Effect of Suppressive DNA on CpG-Induced Immune Activation, J. Immunol. 169: 5590-5594, 2002, (IF:5.788)
  32. R.A. Zeuner, K.J. Ishii, M. Lizak, I. Gursel, H. Yamada, D.M. Klinman, D. Verthelyi, Prevention of inflammatory arthritis by suppressive oligodeoxynucleotides, Arthritis Rheum. 46(8) 2219-2224, 2002, (IF:7.866)
  33. D.M. Klinman, F. Takeshita, I. Gursel, C. Leifer, K.J. Ishii, D. Verthelyi, M. Gursel , CpG DNA: recognition by and activation of monocytes, Microbes Infection, 4(9) 897-901, 2002, (IF:3.101)
  34. K. J. Ishii, F. Takeshita, I. Gursel, M. Gursel, J. Conover, A. Nussenzweig, D. M. Klinman, Potential role of PI3 kinases, rather than DNA-PK, in CpG DNA induced immune activation, J. Exp. Med. 196(2):269-74, 2002, (IF:14.700)
  35. M. Gursel, D. Verthelyi, I. Gursel, K.J. Ishii, D.M. Klinman, Differential and competitive activation of human immune cells by distinct classes of CpG oligodeoxynucleotide, J. Leuko. Biol, 71(5):813-820, 2002, (IF:4.992)
  36. HA Anderson, R. Englert, I. Gursel, E. Shacter, Oxidative stress inhibits the phagocytosis of apoptotic cells that have externalized phosphatidylserine Cell Death Differ. 9(6):616-625, 2002, (IF:8.849)
  37. I. Gursel, M.F.Yagmurlu, F.Korkusuz, V. Hasirci, In vitro antibiotic release from poly(hydroxybutyrate-co-3-hydroxyvalerate) rods, J. Microencapsulation 19:(2)153 -164, 2002, (IF:1.553)
  38. E. Gudemez, F. Eksioglu, P. Korkusuz, E. Asan, I. Gursel, V. Hasirci, Chondroitin sulphate coated hydroxyethyl methacrylate membrane prevents adhesion in full thickness tendon tears in rabbit, J. Hand Surg-Am Ed, 27A: 293-306, 2002, (IF:1.350)
  39. F. Takeshita, C. Leifer, I. Gursel, M. Gursel, K. J. Ishii, D. M. Klinman, Role of Toll-like receptor-9 in CpG DNA induced activation of human cells. J. Immunol. 167(7):3555-3558, 2001, (IF:5.788)
  40. I. Gursel, M. Gursel, K. J. Ishii, D.M. Klinman, Sterically stabilized cationic liposomes improve the uptake and immunostimulatory activity of CpG oligonucleotides, J. Immunol.167(6):3324-3328, 2001, (IF:5.788)
  41. F. Korkusuz, P. Korkusuz, F. Eksioglu, I. Gursel, V Hasirci, In vivo response to biodegradable antibiotic release systems, J. Biomed. Mater. Res. 55:217-228, 2001, (IF:2.625)
  42. I. Gursel, F. Korkusuz, F. Turesin, N.G. Alaeddinoglu, V Hasirci, In vivo application of biodegradable controlled antibiotic release systems for the treatment of implant-related osteomyelitis, Biomaterials 22:(1) 73-80, 2001, (IF:8.404)
  43. F. Turesin, I. Gursel, V. Hasirci, Biodegradable polyhydroxyalkanoate implants for osteomyelitis therapy: in vitro antibiotic release, J. Biomat. Sci-Polym Ed. 12:195-207, 2001, (IF:1.690)
  44. D.M. Klinman, S. Kampstrup, D. Verthelyi, I. Gursel, K. J. Ishii, F. Takeshita, M. Gursel, Activation of the innate immune system by CpG: Therapeutic applications and safety issues, Springer Semin. Immunopathol. 22(1-2): 173-183, 2000, (IF:4.170)
  45. D.M. Klinman, K. J. Ishii, M. Gursel, I. Gursel, S. Takeshita and F. Takeshita, Immunotherapeutic applications of CpG containing oligodeoxynucleotides, Drug News and Perspectives 13(5),289-296, 2000, (IF:2.208)
  46. F.Türesin, Z.Gümüşyazıcı, F.N.Kök, I.Gursel, N.G.Alaadinoğlu, V.Hasırcı, Biosynthesis of Polyhydroxybutyrate and its copolymers and Their use in controlled drug release. Tr. J. Med. Sci. 30:535-541, 2000, (IF:0.139)
  47. D. Sendil, I. Gursel, V.Hasirci, Preparation of PHBV foams and investigation of their potential for drug release, Tr. J. Med. Sci. 30: 9-14, 2000, (IF:0.139)
  48. M.F.Yagmurlu, F.Korkusuz, I. Gursel, P.Korkusuz, U.Ors, V.Hasirci, Sulbactam-cefoperazone polyhydroxybutyrate-co-hydroxyvalerate (PHBV) local antibiotic delivery system: In vivo effectivity and biocompatibility in the treatment of implant related experimental osteomyelitis, J. Biomed. Mater. Res. 46, 494-503, 1999, (IF:2.625)
  49. D. Sendil, I. Gursel, D.L. Wise, and V. Hasirci, Antibiotic Release from biodegradable PHBV microparticles, J. Contr. Rel. 59,207-217, 1999, (IF:7.529)
  50. I. Gursel, C. Balçık, Y. Arica, O. Akkuş, N. Akkaş, V. Hasirci, Synthesis and mechanical properties of interpenetrating networks of polyhydroxybutyrate-co-hydroxyvalerate and polyhydroxyethyl methacrylate, Biomaterials, 19(13):1137-1143, 1998 (IF:8.404)
  51. I. Gursel, Y. Arica, V. Hasirci, Immobilization of glucose oxidase and urease, in hydrogel matrices, Turkish J. Chem. 21(4):387-393, 1997, (IF:0.943)
  52. G. Gregoriadis, I. Gursel, M. Gursel, B. Mc. Cormack, Liposomes as immunological
  53. I. Gursel, C. Balcik, Y. Arica, O. Akkus, V. Hasirci, and N. Akkas, Interpenetrating networks of polyhydroxybutyrate-co-hydroxyvalerate, and polyhydroxyethyl methacrylate: mechanical properties, Engineering Systems Design and Analysis, 5:107-111, 1996
  54. I. Gursel, and V. Hasirci, Microcapsules of PHB and PHBV: morphology and release characteristics, J. Microencapsulation, 12(2):185-193, 1995, (IF:1.553)
  55. I. Gursel, and V. Hasirci, Matrix entrapment of glucose oxidase by gamma-irradiation, Biomaterials, 13(3):150-155, 1992, (IF:8.404)

Chapters In Books

  1.  Z.Tokcaer-Keskin, H. Kocak, I. Gursel and KC. Akcali, Mesenchymal Stem Cells: Possibilities of New Treatment Options, in Adult and Embryonic Stem Cells, edited by K. Turksen, Humana Press, 2011
  2. D M Klinman, K J Ishii, I. Gursel, Immunoprotective activity of CpG oligonucleotide, In. Microbial DNA and Host Immunity, ed. Raz E, Humana Press, 255-263, 2002
  3. S. Bayari, F. Severcan, I. Gursel, V. Hasirci, N. G. Alaeddinoglu, The FTIR studies of PHB and PHBV, In. New Biomedical Materials, eds. P. I. Haris and D. Chapman, IOS Press, 58-64, 1998.
  4. I. Gursel, N. G. Alaeddinoglu, Bacterial polyhydroxyalkanoates: Biosynthesis, screening and characterization, In. Biopharmaceutical and Biomedical Science and Technology, eds. A.A. Hıncal, H. S. Kaş, Plenum Press, NY, USA, 81-88, 1998.
  5. V. Hasirci, I. Gursel, F. Turesin, G. Yigitel, F. Korkusuz, N. G. Alaeddinoglu, In. Biopharmaceutical and Biomedical Science and Technology, Eds. A.A. Hıncal ve H. S. Kas, Plenum Press, NY, USA, 183-187, 1998.
  6. I. Gursel, D. Sendil, D. L. Wise, V. Hasirci, Antibiotic release from biodegradable PHBV microparticles, In. Biopharmaceutical and Biomedical Science and Technology, eds. A.A. Hıncal, H. S. Kaş, Plenum Press, NY, USA, 89-96, 1998.
  7. G.Gregoriadis, I. Gursel, S.G.Antimisiaris, Microbe entrapment in giant liposomes, In: Non-Medical Applications of Liposomes:”From Gene Delivery and Diagnostics to Ecology”, eds. D. L. Lasic and Y. Barenholz, CRC Press, Boca Raton, Vol. IV, 263-269, 1996.
  8. I. Gursel, and V. Hasirci, Transference of solutes across microcapsule membranes In: Recent Advances in Biotechnology, eds, F.V.Sukan, and S.Sukan, NATO ASI Series., Kluwer Academic Publishers, Vol.210:502-503, 1992


International Talks:

  1. Applications of TLR ligands in Anti-cancer therapy and Vaccine development, 2nd International Molecular Immunology & Immunogenetics Congress, Antalya, Turkey, 27-30 April, 2014.
  2. Smart Drug Design, 2nd International Molecular Immunology & Immunogenetics Congress, Antalya, Turkey, 27-30 April, 2014
  3. Extracellular Vesicles as biotherapeutic agents, COST Meeting on Extracellular Vesicles in Health and Diseases, MEHAD (BM1202), Budapest, Hungary, 08-10 April, 2014,
  4. Development and in-vivo performance of long-term acting anti-cancer liposomal vaccines harbouring TLR ligand adjuvants, 6th ILS Liposome Advances Conference-Progress in Drug and Vaccine Delivery, 13-16 Dec, 2013
  5. CpG ODN loaded Exosomes as biotherapeutic agents, COST Meeting (MEHAD) 16-18 May, 2013, Dublin, Ireland
  6. Immunoregulatory action of nucleic acid loaded nanocarrier systems, International Molecular Immunology and Immunogenetics Congress, 2012, 27-29 April, 2012, Antalya, Turkey
  7. Modulation of vaccine immunity via nucleic acid loaded nanocarrier systems, 17th International Symposium on Biomedical Science and Technology (BIOMED 2011), 23-25 November, 2011, Ankara, Turkey, (Invited Talk)
  8. Nucleic acid loaded nanocarrier-mediated modulation of the innate immune response, 17-18-August, 2011, TRON Meeting,Germany,
  9. Strategies to improve the in vivo potency of TLR-Therapeutics, 1st Turkish-German Workshop on Nanobio-and Biosensing Technologies, 20-21 June, 2011, Ankara, Turkey
  10. CpG-motif mediated modulation of the immune response, 30th Congress of the European Academy of Allergy and Clinical Immunology, EAACI 2011, 11-15 June 2011, Istanbul, Turkey (Introductory Lecture)
  11. Molecular methods for disease marker identification, 30th Congress of the European Academy of Allergy and Clinical Immunology, EAACI 2011, 11-15 June 2011, Istanbul, Turkey (Invited Talk)
  12. Strategies to Improve TLR-based Immunotherapeutics, Advances in Immunology and Cancer Biology Workshop, 15-17 Apr, 2011, Istanbul, Turkey
  13. How to improve the potency of TLR-based immunotherapy, Immunology Frontier Research Center (IFREC), Osaka University, 17 Jan, 2011, (Invited Talk)
  14. Biotherapeutic Oligodeoxynucleotides Research Lab Experiences in Bilkent University, MBG Department and Suggestions to the Turkish German University, Life Sciences Faculty Establishment, Workshop on Turkish-German University, Potsdam, Germany, 13-16 November, 2010,
  15. Liposomes: Versatile lipid vesicles for nanomedical applications, Winter School on Frontiers in Nanomedicine and Nanobiotechnology, January, 10-13, 2010, Ankara, Turkey
  16. Strategies to enhance nucleic acid delivery to immune cells, Workshop on Current Trends in Molecular Nanobiosciences, January 13-16, 2010, Ankara, Turkey
  17. Nanobiotechnological Applications of Self Assembled Immunostimulatory DNA Nanoparticles, BIOMED2009, 16-19 Aug, 2009, Guzelyurt T.R.N. Cyprus (Invited speaker)
  18. Immunostimulatory DNA Nanoparticles, Nanobio Europe-2009, 16-18 June, 2009, Grenoble, France (Invited speaker)
  19. Introduction to PAMPs and Activation of Innate Immunity, 14th European Paediatric Rheumatology Congress, Sept. 2007, Istanbul, Turkey, (Invited speaker)
  20. Nanobiotechnology: New horizons in 21st Century: Nanobiotechnology Potential, Workshop on Molecular Biology and Genetics, August 2007, Girne, TRNC, (Invited speaker)
  21. TLR9 agonists and antagonists: potential immunotherapeutic applications, Aug 2006, Gulbenkian Institute of Sciences, Lisbon, Portugal (Invited Talk)
  22. Immunotherapeutic applications of CpG ODN, June 2006, 31st FEBS Congress, Istanbul, Turkey (Invited talk)
  23. Bacterial and mammalian DNA: immunomodulatory action, Univ Otago, School of Pharmacy, Annual Immunology/Virology Meeting, July 2004, Dunedin, New Zealand (Plenary lecture).
  24. Repetitive elements present in mammalian telomeres suppress CpG DNA induced immune activation. NIH Immunology Retreat, Oct, 2003, Airlie, Virginia, USA (Selected talk).
  25. In vivo immune responses induced by CpG oligonucleotides encapsulated in sterically stabilized cationic liposomes, 28th International Symposium on Controlled Release of Bioactive Materials, June 2001, San Diego, California, USA (Invited talk).
  26. Efforts to improve the effectiveness of oligodeoxynucleotides expressing immunostimulatory CpG motifs: studies of PEGylated CpG ODN and ODN/PNA chimeras, Immunology Retreat, Oct 1999, Airlie House, Virginia, USA (Selected talk).
  27. The production and application of microbial polyesters in the construction of biodegradable controlled antibiotic release systems. 11th Gordon Research Conferences on Drug Carriers in Medicine and Biology, Feb.1998 Los Angeles, California, USA (Selected presentation).
  28. Microbial biosynthesis of polyhydroxybutyric acids: Screening and characterization, 4th Int.Symp. on Biomedical Science and Technology, Aug. 1997, Istanbul, Turkey (Invited talk).
  29. Potential multiple vaccine carrier: Giant vesicles and multilamellar giant DRV’s, 8th International Pharmaceutical Technology Symposium: Recent advances in peptide and protein delivery, sept. 1996, Ankara, Turkey (Invited talk).
  30. Liposome Workshop, DCIEM Research Liposome Workshop, Oct. 1993, Toronto, Canada (Plenary lecture).

National Talks:

  1. Designing DNA nanoparticles as Anti-Cancer Therapeutic Agents, Turkish R&D Summit and Fair, Istanbul, Turkey, 13-15, May, 2014
  2. DNA Nanoparticles, Ankara University, Medical School, Ankara, Turkey, 5 February, 2014
  3. DNA as a Nanodrug, Acibadem University, Medical School, Istanbul, Turkey,16 May, 2014
  4. What Can DNA do for You: Nanobiotechnological Application of DNA Nanoparticles, METU, Biological Sciences Dept. Ankara, Turkey, 11 June, 2014
  5. Immunostimulatory role of CpG motifs: A potent Adjuvant for Vaccines, VETAL LTD STI, Adiyaman, Turkey, 28 June, 2014
  6. Good Things Come in Small Packages: Immunotherapeutic Applications of DNA-loaded Exosome Nano-vesicles, İYTE, İzmir, Turkey, 8 April 2013.
  7. Cell Culture Techniques, and Applications, 2-day Course, for NUVE Company, 45th Foundation Year Anniversary, May 2013, Antalya, Turkey
  8. Applications of TLR ligands in Anti-cancer therapy and Vaccine development, 22nd National Immunology Congress, Izmir, Turkey, 27-30 April, 2013.
  9. Inflammasomes: Intracellular sensors of microbes and danger, 20nd National Congress of Allergy and Clinical Immunology, Antalya, Turkey, 2-6 November, 2013.
  10. Contribution of nanotechnology to immunomodulation, 19th National Allergy and Clinical
  11. Immunology Congress, 9th November, 2012
  12. Immunotherapeutic and nanomedicine applications of nucleic acid based nanoparticles, XII National Medical Biology and Genetics Congress, 27-30 October, 2011, Antalya, Turkey, (Invited Talk)
  13. Use of transcriptome data to unravel the genes involved in immunomodulatory ODN mediated immune activation in mice, Bioinformatics for Anti-Cancer Drug Discovery Workshop, 17-18 October 2011, Ankara, Turkey
  14. Contribution of nanobiosciences to applied immunology: More effective imunotherapeutic applications of TLR ligands, 21st National Immunology Congress, 6-9 April 2011, Marmaris, Turkey
  15. Nanobiotechnology: New opportunities and challenges in the horizon, Symposium on Application of Nanomedicine: Cancer, Aging and Stem Cell, 13 Dec, 2010, Acibadem University, Istanbul, Turkey
  16. New horizons in nanobiotechnology: applications of DNA as a nanodrug, Ankara University, Medical School, (Invited Lecture), 28 April, 2010, Ankara, Turkey
  17. DNA Nanoparticles: Potential applications as a biotherapetic agent in infectious diseases, cancer, and autoimmunity, Hacettepe University, Medical School, Nanotechnology Center, (Invited Talk), 12 April, 2010, Ankara, Turkey
  18. Nanobiotechnology, a new horizon in medicine and Biotechnology, opportunities for Turkish R&D Sector. (Panel member), Life Sciences and Health Technologies Workshop, Bosphorus University, 22-23 Aralik 2009, Istanbul, Turkey
  19. Epigenetics Regulation of Allergic and Asthmatic Disorders, XVII, National Allergy and Clinical Immunology Congress, Antalya, 3-7 November, 2009 (Invited speaker)
  20. Toll Like Receptors: Master Molecules Mediating Inflammation, 20. National Pharmacology Congress, 4-7 November, 2009, Antalya, Turkey (Invited speaker)
  21. The Contribution of Nanotechnology in Turkish Bio-Medical Research Applications, 5th Oncologic Research Workshop and Courses, 10-15 November, 2009, Antalya, Turkey (Invited speaker)
  22. Potential Nanomedical Applications of Self Assembled Immunomodulatory DNA Nanoparticles, NANOTR-V, 8-12 June, 2009, Eskisehir, Turkey (Invited speaker)
  23. Utilization of Immunosuppressive DNA Motifs in the Treatment of Neurological Diseases, Hacettepe Medical School, Dept of Neurology, 26 Apr. 2009, Ankara, Turkey (Invited tutorial)
  24. Immunotherapeutic Applications of DNA Based Nanodrugs, GATA Medical School, Dept. of Rheumatology, 14 Apr. 2009, Ankara, Turkey (Invited tutorial)
  25. Applications of Nanotechnology in Medicine, 12th National TORAKS Meeting, 8-12 Apr, 2009, Antalya, Turkey (Invited speaker)
  26. DNA Vaccines and Innate Immunity, National Gastroenterology Week, 12-16 Nov, 2008, Adana Turkey (Course tutorial)
  27. Mechanisms of CpG ODN mediated immune activation, XX. National Biochemistry Congress, 29 Oct-1Nov/2008, Nevşehir, Türkiye (Invited speaker)
  28. Immunotherapeutic applications of DNA nanoparticles in cancer, infectious and autoimmune diseases BİYOMUT’08, (13. National Biomedical Engineering Meeting), 29-31/May/2008, Ankara) (Invited speaker)
  29. Immunoregulatory Role of TLR9 Agonist CpG DNA, 19th National Immunology Congress, Nov 2007, Antalya, Turkey, (Invited speaker)
  30. Nanotechnology and Nanomedicine, 21st National Physical Medicine and Rehabilitation Congress, Oct. 2007, Antalya, Turkey, (Invited speaker)
  31. Nanotechnology in Asthma and Allergy, XV. National Allergy and Clinical Immunology Congress, Oct. 2007, Antalya, Turkey, (Invited speaker)
  32. DNA Nanoparticles: Potential Nanobiotechnological Applications 13th BIOMED Symposium, August, 2007, Istanbul, Turkey (Invited speaker)
  33. Potential Nanobiotechnological Applications of DNA Nanoparticles, NanoTR-III, Nanoscience, Nanotechnology, Nanobiotechnology, and Nanomedicine Conference, June 2007, Ankara, Turkey, (Invited speaker)
  34. Immunotherapeutic Potential of TLR9 Agonists and Antagonists, 7th National Chromatography Congress, June 2007, Kirikkale, Turkey
  35. DNA Nanoparticles: potential nanobiotechnological applications, Workshop on Molecular Biomimetics and Bionanotechnology, Nov 2006, Istanbul, Turkey (Invited speaker)
  36. A new horizon in nanobiotechnology: DNA nanoparticles Oct 2006, TOBB University, Ankara, Turkey (Invited speaker)
  37. DNA containing nanoparticles: potential applications in nanotechnology, Oct 2006, Nanotechnology Research Forum, METU, Ankara, Turkey (Invited speaker)
  38. Molecular mechanisms mediating protection by innate immune cells, May 2006, VII. Prenatal Diagnostic and Medical Genetics Congress, Kayseri, Turkey (Invited lecture)
  39. CpG DNA nanoparticle: enhanced in-vivo immunoregulatory activities, May 2006, NANOTR II (Nanoscience and Nanotechnology II), Ankara, Turkey (Invited lecture)
  40. Nanoparticle mediated targeting of immunostimulatory DNA to treat infectious diseases, April 2006, GATA, Medical School, Ankara, Turkey (Invited lecture)
  41. Immunosuppressive potential of mammalian DNA expressing TTAGGG motifs and their utilization as a molecular drug to treat autoimmune diseases. April 2006, Hacettepe University, Medical School, Genetics Institute, Ankara, Turkey (Invited lecture)
  42. Liposome encapsulating CpG DNA: enhanced in vivo activity and immunomodulatory action, April 2006, Bosphorus University, Istanbul, Turkey (Invited lecture)
  43. Immunoprotective potential of Bacterial DNA expressing CpG motifs, March 2006, Hacettepe University, Medical School, Pediatric Allergy Department, Ankara, Turkey (Invited lecture)
  44. TLR9 Therapeutics: from bench to bedside, Dec,2005, Dokuz Eylul University, Medical School, İzmir, Turkey (Invited lecture).
  45. Gene array analyses of immune cells treated with CpG DNA, Nov 2005, HİBİT’05, Antalya, Turkey (Invited talk).
  46. Toll like receptor 9 agonists and antagonists: mode of action and therapeutic applications, Oct 2005, METU, Dept. Biol. Sci., Ankara Turkey (Invited lecture).
  47. Immunoregulatory properties of TLR9 agonists and antagonists. XVIII, National Immunology Symposium, Sept, 2005, Bursa, Turkey (Invited talk).
  48. Immunoregulatory activity of CpG and suppressive oligodeoxynucleotides. Faculty of Engineering and Natural Sciences, Sabanci University, May 2004, Istanbul, Turkey (Invited lecture). Protection of liposomal antigen from specific antibody attack in vitro, 14th National Congress of Biochemistry, Sept.1997, Izmir, Turkey (Invited talk).
  49. Immunomodulatory effects of bacterial and mammalian DNA, Dept. Biology, Middle East Technical University, May 2004, Ankara, Turkey (Invited lecture).
  50. Use of giant vesicles as potential vaccine carriers: Immunization studies, Biomed 3, 3rd National Symposium on Biomedical Science and Technology, Dec. 1996, Bursa, Turkey (Invited talk).


  1. Exosomes as immunotherapeutic nanocarriers of TLR agonists and antagonists.
  2. Immune modulation of innate immune system utilizing TLR based ligands formulated within nanodelivery systems.
  3. Immunoprotective, anti-cancer and immunoadjuvant effects of synthetic oligodeoxynucleotides expressing CpG motifs.
  4. The role of Toll-like receptor (TLR) and TLR-ligand interactions (alone or in combination) to trigger improved innate immune response.
  5. Immunoregulatory effects of immunosuppressive mammalian DNA motifs.
  6. Gene expression and transcriptional profiling of immune cells triggered with TLR agonists and antagonists using gene chips.
  7. Designing controlled release systems for oligodeoxynucleotide targeting and delivery.
  8. Applications of biodegradable, natural macromolecules for nanobiotechnology, tissue engineering, biomaterials, and drug delivery.


  1. Journal of Allergy and Clinical Immunology (IF: 11.248)
  2. Nature Reviews in Rheumatology (IF: 10.252)
  3. Annals of Rheumatoid Diseases (IF: 9.111)
  4. Biomaterials (IF: 8.312)
  5. Nucleic Acid Research (IF: 8.278)
  6. Biomacromolecules (IF: 5.788)
  7. Journal of Leukocyte Biology (IF:4.568)
  8. Plos One (IF: 3.730)
  9. Mediators of Inflammation (IF: 3.883)
  10. Carbohydrate Polymers (IF: 3.479)
  11. Investigational Ophtalmology and Visual Science (IF: 3.441)
  12. BMC Cancer (IF: 3.332)
  13. Vaccine (IF: 2.598)
  14. Journal of Immunological Methods (IF: 2.225)
  15. Frontiers in Immunology (IF: will be announced in July 2015)


  1. Organizing Committee member of the 23. National Congress on Immunology (26-30 Apr. 2015)
  2. Co-Organizer of 4th Molecular Biology and Genetics Congress in Ankara (01-04-Oct. 2015)
  3. Winter School on Frontiers in Nanomedicine and Nanobiotechnology” Bilkent University,10th -13th Jan. 2010 (http://www.fen.bilkent.edu.tr/~regpot/winterschool2010/), Ankara, Turkey
  4. Workshop on Current Trends in Molecular Nanobiosciences” Bilkent University,13th -16th Jan. 2010 (http://www.fen.bilkent.edu.tr/~regpot/workshop2010/), Ankara, Turkey
  5. Biomed-2, 2nd National Symposium on Biomedical Science and Technology, 21-23 Sept 1995 Ankara, Turkey (organizing committee member)
  6. School of Mediterranean Universities for Biotechnology, 20-27 Sept. 1992, Ankara, Turkey (organizing committee member)


  • Biotechnology Congress,
  • National Immunology Congress,
  • National Biomedical Science and Technology Symposium (BIOMED),
  • Allergy and Clinical Immunology Congresss,
  • National Symposium on Biomedical Science and Technology.


  • Association of American Immunologists, Washington DC, USA
  • American Academy of Advancement of Science, Washington DC, USA
  • Controlled Release Society, Washington, USA
  • TASSA (Turkish American Scientists and Scholar Association), founding member, Washington DC, USA
  • International Society of Extracellular Vesicles, (ISEV), Sweden, founding member,
  • Biomaterials and Tissue Engineering Society, founding member, Ankara, Turkey
  • Turkish Immunology Society, Istanbul, Turkey
  • Turkish Biochemical Society, Ankara, Turkey
  • Turkish Biotechnology Society, Ankara, Turkey